Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae in Urinary Tract Infections: Current Challenges and Future Perspectives
International Journal of Advanced Research in Science Communication and Technology · 13.06.2026 · 536
DOI: 10.48175/ijarsct-36557 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Advanced Research in Science Communication and Technology, online erschienen am 13.06.2026. Verfasst von Shiva Yadav. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Escherichia coli and Klebsiella pneumoniae are responsible for the majority of urinary tract infections (UTIs). UTIs are among the most prevalent infections in humans globally and therefore pose a significant public health problem (1,2). As a result of its nocturnal position as one of the most important Uropathogen responsible for either community-acquired or hospital-acquired UTIs, Klebsiella pneumoniae is now regarded as a significant medical threat (1). The increasing number of ESBL-producing Klebsiella pneumoniae, especially within the last two decades, has made it increasingly difficult to treat these infections; the number of effective treatment options has diminished due to the emergence of this pathogen, which is resistant to multiple antibiotic classes (2,3). As a result of the resistance exhibited by ESBL-producing Klebsiella pneumoniae to many β-lactam antibiotics in particular, the option of using extended-spectrum cephalosporins and monobactams as treatment options for these infections is significantly reduced (2). Therefore, the increased incidence of morbidity, mortality, and healthcare costs associated with the use of antibiotics to treat UTIs caused by ESBL-producing Klebsiella pneumoniae is due to the fact that ESBLs hydrolyze extended-spectrum cephalosporins and monobactams (3,4). This review will examine the epidemiology, pathogenesis, virulence factors, and mechanisms of ESBL production in Klebsiella pneumoniae UTI infections, discuss patterns of antimicrobial resistance, and summarize the diagnostic and treatment methods and emerging therapeutic alternatives associated with this pathogen(5). The review will also highlight some of the challenges associated with multidrug-resistant strains of Klebsiella pneumoniae causing UTIs and will provide a future perspective on infection control, antibiotic stewardship, and novel therapeutic interventions. An understanding of the evolving resistance of Klebsiella pneumoniae to antibiotics, especially ESBL-producing strains, will be important for the development of appropriate therapeutic strategies to reduce the global impact of antimicrobial resistance and the occurrence of UTIs (4,5).
Zitieren
APA
Yadav, S. (2026). Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae in Urinary Tract Infections: Current Challenges and Future Perspectives. International Journal of Advanced Research in Science Communication and Technology, 536. https://doi.org/10.48175/ijarsct-36557
Vancouver
Yadav S. Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae in Urinary Tract Infections: Current Challenges and Future Perspectives. International Journal of Advanced Research in Science Communication and Technology. 2026:536. doi:10.48175/ijarsct-36557
BibTeX
@article{Yadav2026,
author = {Yadav, Shiva},
title = {Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae in Urinary Tract Infections: Current Challenges and Future Perspectives},
journal = {International Journal of Advanced Research in Science Communication and Technology},
year = {2026},
pages = {536},
doi = {10.48175/ijarsct-36557}
}
EUVIMED